Discovery of <i>N</i>-sulfonylated aminosalicylic acids as dual MCL-1/BCL-xL inhibitors-Reference-Cited by-同舟云学术

Discovery of N-sulfonylated aminosalicylic acids as dual MCL-1/BCL-xL inhibitors

Published:2023 Issue:1 Volume:14 Page:103-112
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Chen Lijia¹,Chauhan Jay¹,Yap Jeremy L.¹,Goodis Christopher C.¹,Wilder Paul T.²³,Fletcher Steven¹³^ORCID

Affiliation:

1. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 N. Pine St., Baltimore, MD 21201, USA

2. University of Maryland School of Medicine, 20 S. Greene St., Baltimore, MD 21201, USA

3. University of Maryland Greenebaum Cancer Center, 20 S. Greene St., Baltimore, MD 21201, USA

Abstract

Deconstruction of a bicyclic tetrahydroquinoline-6-carboxylic acid scaffold into aminosalicylic acids yielded dual MCL-1/BCL-xL inhibitors from an MCL-1 selective lead.

Funder

National Institute of General Medical Sciences

University of Maryland

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/MD/D2MD00277A

Reference35 articles.

1. BCL-2 family proteins: changing partners in the dance towards death

2. The BCL-2 arbiters of apoptosis and their growing role as cancer targets

3. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies

4. MCL-1 inhibitors – where are we now (2019)?

5. Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The design, synthesis, biological evaluation, and molecular docking of new 5‐aminosalicylamide‐4‐thiazolinone hybrids as anticancer agents;Archiv der Pharmazie;2023-08-08

2. Tetrazole and acylsulfonamide bioisosteric replacements of the carboxylic acid in a dual MCL-1/BCL-x_L inhibitor are tolerated;RSC Advances;2023